These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. In vitro neurotoxicity of magnetic resonance imaging (MRI) contrast agents: influence of the molecular structure and paramagnetic ion. Bertin A; Michou-Gallani AI; Gallani JL; Felder-Flesch D Toxicol In Vitro; 2010 Aug; 24(5):1386-94. PubMed ID: 20460148 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of nonionic paramagnetic metal complexes as potential magnetic resonance imaging contrast agents. White DH; Rajagopalan R; Kuan KT; Lin Y; Wallace RA; Rogic MM; Bosworth ME; Robbins MS; Ralston WH; Adams MD Invest Radiol; 1990 Sep; 25 Suppl 1():S56-7. PubMed ID: 2126534 [No Abstract] [Full Text] [Related]
9. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function. Sidhu MK; Muller HH; Aggeler J; Jones AL; Young SW Invest Radiol; 1993 Oct; 28(10):903-10. PubMed ID: 8262744 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of manganese-trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging]. Usov VIu; Balianin ML; Bezlepkin AI; Churin AA; Dubskaia TIu; Vetoshkina TL; Filimonov VD Eksp Klin Farmakol; 2013; 76(10):32-8. PubMed ID: 24400387 [TBL] [Abstract][Full Text] [Related]
11. Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy. Grant D; Zech K; Holtz E Invest Radiol; 1994 Jun; 29 Suppl 2():S249-50. PubMed ID: 7928247 [No Abstract] [Full Text] [Related]
12. Normal and infarcted myocardium: differentiation with cellular uptake of manganese at MR imaging in a rat model. Bremerich J; Saeed M; Arheden H; Higgins CB; Wendland MF Radiology; 2000 Aug; 216(2):524-30. PubMed ID: 10924581 [TBL] [Abstract][Full Text] [Related]
13. Effects of Mn-DPDP and manganese chloride on hemodynamics and glucose tolerance in anesthetized rats. Gao X; Sandberg M; Quach M; Bodin B; Johansson L; Jansson L Acta Radiol; 2014 Apr; 55(3):328-34. PubMed ID: 23963152 [TBL] [Abstract][Full Text] [Related]
14. Liver-specific contrast agents for MRI. Stark DD; Elizondo G; Fretz CJ Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535 [No Abstract] [Full Text] [Related]
15. Charge dependence of the distribution of contrast agents in rat cerebral ventricles. Wan X; Fu TC; London RE Magn Reson Med; 1992 Sep; 27(1):135-41. PubMed ID: 1435199 [TBL] [Abstract][Full Text] [Related]
16. A new opportunity for MEMRI. Cloyd R; Vandsburger M; Abisambra JF Aging (Albany NY); 2017 Aug; 9(8):1855-1856. PubMed ID: 28854148 [No Abstract] [Full Text] [Related]
17. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver. Tanimoto A; Kuribayashi S Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158 [TBL] [Abstract][Full Text] [Related]
18. Liposomes as MR contrast agents: pros and cons. Unger E; Shen DK; Wu GL; Fritz T Magn Reson Med; 1991 Dec; 22(2):304-8; discussion 313. PubMed ID: 1812361 [TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced magnetic resonance imaging of the liver with Mn-DPDP for known or suspected focal hepatic disease. Bernardino ME; Young SW; Lee JK; Weinreb J Invest Radiol; 1991 Nov; 26 Suppl 1():S148-9; discussion S150-5. PubMed ID: 1808113 [No Abstract] [Full Text] [Related]
20. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Rummeny E; Ehrenheim C; Gehl HB; Hamm B; Laniado M; Lodemann KP; Schmiedel E; Steudel A; Vogl TG Invest Radiol; 1991 Nov; 26 Suppl 1():S142-5; discussion S150-5. PubMed ID: 1808111 [No Abstract] [Full Text] [Related] [Next] [New Search]